Skip to main content

Table 3 Clinical parameters at presentation, treatments given, and outcome data for the two groups either receiving or not receiving plasma exchange (PEX) as part of disease induction

From: Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service

Characteristic No PEX (n = 46) PEX (n = 58) p value
At presentation    
Creatinine (μmol/l) 140 ± 90 370 ± 259 0.000
eGFR (ml/min/1.73 m2) 56 ± 31 22 ± 22 0.000
CRP (mg/l) 48 ± 61 105 ± 82 0.001
Haemoglobin (g/l) 116 ± 21 94 ± 18 0.000
Albumin (g/l) 34 ± 6 29 ± 6 0.000
Dialysis-requiring 1a 20 0.000
VDI 0 0 1
Induction period (~3 months)
Number (%) of patients receiving
Glucocorticoids 46 (100) 58 (100) 1
CYC 23 (50) 45 (78) 0.004
Rituximab 15 (33) 7 (12) 0.03
CYC and/or rituximab 38 (83) 52 (90) 0.39
MMF 8 (17) 16 (28) 0.24
Methotrexate 8 0 0.001
Azathioprine 6 1 0.02
Infliximab 1 0 0.25
Cumulative glucocorticoid dose (g) 2.5 ± 0.4 2.3 ± 0.2 0.000
Cumulative CYC dose (g) 8.0 ± 3.6 5.4 ± 3.0 0.002
Disease remission    
Number (%) entering remission 44 (96) 57 (98) 0.98
Time to remission (days) 118 ± 124 83 ± 39 0.046
At 12 months    
Creatinine (μmol/l) 120 ± 46 191 ± 172 0.02
eGFR (ml/min/1.73 m2) 56 ± 24 43 ± 24 0.02
CRP (mg/l) 22 ± 71 8 ± 14 0.33
Haemoglobin (g/l) 126 ± 14 121 ± 15 0.15
Albumin (g/l) 41 ± 6 40 ± 5 0.31
Dialysis-requiring 0 5 0.04
VDI 1.2 ± 0.2 1.3 ± 0.1 0.79
Disease relapse    
Number (%) of patients with relapses 12 (26) 8 (14) 0.09
Mean time to first relapse (days) 714 ± 699 564 ± 318 0.38
Median time to first relapse 800 (1124) 773 (1164) 0.57
(days & IQR)    
  1. CRP C-reactive protein, CYC cyclophosphamide, eGFR estimated glomerular filtration rate, IQR interquartile range, MMF mycophenolate mofetil, VDI Vasculitis Damage Index. Data are shown as either mean ± standard deviation or median and IQR. aThis patient did not receive PEX as it was not tolerated alongside dialysis